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Abstract
Background: To provide a clear picture of the current hepatitis B situation, the authors performed a systematic
review to estimate the age- and region-specific prevalence of chronic hepatitis B (CHB) in Turkey.
Methods: A total of 339 studies with original data on the prevalence of hepatitis B surface antigen (HBsAg) in
Turkey and published between 1999 and 2009 were identified through a search of electronic databases, by
reviewing citations, and by writing to authors. After a critical assessment, the authors included 129 studies, divided
into categories: ‘age-specific’; ‘region-specific’; and ‘specific population group’. To account for the differences
among the studies, a generalized linear mixed model was used to estimate the overall prevalence across all age
groups and regions. For specific population groups, the authors calculated the weighted mean prevalence.
Results: The estimated overall population prevalence was 4.57, 95% confidence interval (CI): 3.58, 5.76, and the
estimated total number of CHB cases was about 3.3 million. The outcomes of the age-specific groups varied from
2.84, (95% CI: 2.60, 3.10) for the 0-14-yearolds to 6.36 (95% CI: 5.83, 6.90) in the 25-34-year-old group.
Conclusion: There are large age-group and regional differences in CHB prevalence in Turkey, where CHB remains a
serious health problem.
Background
Globally, hepatitis B is one of the most common infec-
tious diseases. Estimates indicate that at least 2 billion
people have been infected with the hepatitis B virus
(HBV), with more than 378 million people being
chronic carriers (6% of the world population). Of all
chronic hepatitis B (CHB) cases, approximately 40% will
develop cirrhosis, liver failure, or hepatocellular carci-
noma (HCC) [1,2]. According to the World Health
Organization (WHO) classification, Turkey is one of the
countries with intermediate (2%-8%) endemicity for
hepatitis B. This information has been derived mainly
from studies in blood donors. Based on these data, the
overall prevalence of the hepatitis B surface antigen
(HBsAg), which is a marker for chronic hepatitis B
infection, has been reported to be between 4.0% and
5.0% [3], which has decreased to 2.0% in recent years
[4]. However, this HBsAg prevalence appears to differ
considerably in various parts of the country. For exam-
ple, a study on the seroprevalence of HBV in children in
Eastern Anatolia reveals an HBsAg prevalence of 9.8%
[5]. There is no clear picture of the current HBV situa-
tion in Turkey. A national vaccination program for the
prevention of perinatal transmission of hepatitis B infec-
tion was launched in Turkey in 1998. Currently there is
no routine HBsAg screening program for pregnant
women in Turkey. All infants are vaccinated at birth
and followed up at 1 month and again at 6 months of
age.
For the planning and implementation of adequate
health promotion and intervention measures, it is
important for both health care providers and policy
makers to know the real burden of CHB in region- and
population-specific groups. In addition, migration from
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any medium, provided the original work is properly citedTurkey to the European Union (EU) has important pub-
lic health implications. Prevalence of hepatitis B in
migrant populations in low endemic EU countries is
likely to reflect the prevalence of their region of origin.
It is of value for EU countries with Turkish migrants to
know the country-specific prevalence of hepatitis B in
order to make health policy decisions for migrants in
their country [6]. This is particularly important for the
timely identification and treatment of chronic HBV car-
riers. In order to make a best estimate for the age-speci-
fic, region-specific, and country-specific prevalence of
HBsAg, we performed a systematic review of the litera-
ture on HBsAg prevalence in Turkey, focussing on age-
and region-specific prevalence rates.
For optimal insight into the HBsAg prevalence in Tur-
key we included several study types: (i) studies employ-
ing random cluster sampling in the population; (ii)
large-scale studies among blood donors and military
conscripts; (iii) studies in various groups that have
health-related concerns such as pregnant women and




This systematic review conforms to the guidelines out-
lined by the Meta-Analysis of Observational Studies in
Epidemiology (MOOSE) [7]. For English and/or Turkish
language studies, the databases MEDLINE, PUBMED,
EMBASE and UlakBim (Turkish Medical Index) were
searched by using the following terms: ‘Hepatitis B [and]
Turkey’, ‘HBsAg prevalence [and] Turkey’. All articles
were reviewed and their corresponding reference lists
inspected to identify additional material, including
unpublished (grey) literature, which initially had not
been detected. These were later either retrieved by a
new electronic search or searched manually. The period
for the meta-analysis for the age- and region-specific
studies ranges from 1999-2009, so the data is coupled
with results obtained after the advent of the universal
immunization program in Turkey in 1999. HBsAg pre-
valence was estimated within 7 broad age groups (0-14,
15-24, 25-34, 35-44, 45-54, 55-64, and 65 years and
older). The age groups were selected to best fit the
available data extracted from the literature. For the stu-
dies on health care workers, a comparison was made
between the studies from 1990-1999 and 2000-2009, in
order to retrieve the risk group vaccination effect.
Eligibility criteria
First-round review criteria for selection of studies
included were the availability of explicit data on the
country region, setting (e.g., hospital), study period, risk
group studied, number of subjects studied, and number
of subjects positive to HBsAg, or stated crude preva-
lence. Information related to age-specific outcome was
also extracted. We took measures to detect and extract
overlapping reports on the same study population.
These measures included comparing the study period,
sample size, centres where studies were performed, and
author names.
The provinces of Turkey comprise 7 census-defined
regions (bölge). For the purpose of this study, we pooled
some regions together based on several factors such as
geography, population size, and socioeconomic status.
The following division of regions was done; Region A:
Marmara and Aegean region; B: Black Sea, Central Ana-
tolia and Mediterranean region; C: Eastern and south-
eastern region (Figure 1).
Data extraction and data analysis
Once a study was included, the following data were
extracted and entered into tables: age group, study
region, population type in terms of risk, total number of
persons studied, number of persons positive for HBsAg,
and year of publication. Two of the authors (MT and
FOÖ) checked all data used in the analysis. When dis-
agreement arose, these were resolved by consensus. The
unpublished studies (grey literature) were included in
the analysis if they met the inclusion criteria. The
unpublished material consists of abstracts presented at
conferences and of personal communication with clini-
cians who designed the sero-epidemiology studies. The
names and affiliations of the authors and the settings of
the unpublished studies are listed in the Additional file
1: Appendix and referred to separately from the pub-
lished literature.
Age- and region-specific randomized community
sampling
The meta-analysis and data synthesis were done sepa-
rately for the studies that included both region- and
age-specific prevalence data, since these studies were
mainly randomized community sampling. Most studies
did not use a random sample from the population in
each age group and sample or differed with respect to
the year in which the sample was gathered. As a
result, significant differences in the estimated preva-
lence may occur even within age groups and regions.
To account for the differences among the included
studies, a generalized linear mixed model was used to
estimate the overall prevalence across all age groups
and the 3 regions. In this model, we apply a logit link
function and a binomial response distribution (similar
to logistic regression) to predict the dependent vari-
able, HBsAg positivity. The logit function is one of
the most commonly used link functions for the bino-
mial distribution.
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stant term, the categorical variables age and region, and
a random intercept for each to account for unexplained
variation in prevalence. The overall prevalence was esti-
mated as the predicted value from a model that con-
tained only a fixed intercept and a random intercept for
the different studies. The model parameters were esti-
mated using data from all studies and also separately,
using only data from published studies. Model fit was
evaluated from plots of the studentized residuals as a
function of the linear predictor. The same method was
used with region as a predictor to obtain region-specific
estimates. These models were fitted with proc glimmix
in SAS version 9.2 using adaptive Gaussian quadrature
to approximate the log-likelihood function. From the
data of these randomized community-sampling studies,
we calculated the exact binomial 95% confidence inter-
val (CI) for the crude prevalence of each study. For such
CI calculations, we made the assumption that each
study used a random sample from the population.
Other studies
We calculated the weighted mean prevalence (WMP) to
limit the bias caused by the heterogeneous nature of the
reports. WMP was calculated as follows:WMP =
∑ωiprevi/∑ωiw h e r eωi =1 / [ p r e v i(1-previ)/Ni], previ is
the fraction of (HBsAg positive patients) in study i,a n d
Ni is the number of patients in study i.W M Pi s
regarded as the most accurate method to estimate
HBsAg prevalence when considering several reports
[8-10]. This method has proven to be reliable when
combining a number of studies with inherent heteroge-
neity in sample and effects size [11]. This heterogeneity
c a nb ec a u s e db yas m a l ld i f f e r e n c ei nt h ew a yt h a t
patients are sampled in the population or by differences
in the year of the study. The WMP was calculated for
all data (published and unpublished); in addition, for the
published data separate, two-sided Mann-Whitney tests
were used to compare the prevalence distribution of
published and unpublished studies.
Results
General scope
The results of the search strategy and final distribution
of the studies are shown in Figure 2. The electronic
search identified 254 papers, and manual reference
checking identified an additional 84 references; we also
received 1 unpublished dataset on military recruits. Out
of the 197 studies that were reviewed, 136 studies were
in Turkish, of which 19 were finally excluded. The list
of references arranged by various criteria can be found
in Tables 1, 2, 3 &4. The systematic review identified
129 studies that provided prevalence estimates that were
split into different subgroups.
Age- and region-specific studies
Thirty studies, of which 22 were published [12-33] and 8
unpublished (Additional file 1: Appendix; a-h), reported
the age- and region-specific prevalence of hepatitis B.
B o t ht h ea g e -a n dr e g i o n - s p e c i f i cp r e v a l e n c ea n dt h e
Figure 1 Map of Turkey according to regions, population size per region and the number of estimated CHB cases.M a po fT u r k e y
according to regions; 1: Marmara region, 2: Aegean region, 3: Black Sea region, 4: Inner Anatolia region, 5: Mediterranean region, 6: Eastern
Anatolia region, 7: south-eastern Anatolia region. Regions with similar socioeconomic status and HBsAg seroprevalence are grouped as A (1 and
2), B (3, 4 and 5) and C (6 and 7).
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overall age group prevalence for regions A, B, and C
yields 3.52 (95% CI: 1.92, 5.11), 4.95 (95% CI: 3.06,
6.83), and 6.76 (95% CI: 4.58, 8.93), respectively. Figure
3 shows the age group and region-specific curves of the
pooled prevalence data. The estimated overall popula-
tion prevalence was 4.57% (95% CI 3.58, 5.76). The gen-
eralized linear mixed model was used to also estimate
t h ep r e v a l e n c eu s i n go n l yt h ep u b l i s h e dd a t a ,w h i c h
yielded a population prevalence of 5.10 (95% CI: 4.22,
6.34). When this prevalence is extrapolated to the total
population living in Turkey (71.5 million), the total
number of CHB cases will be about 3.3 million (Figure
1). We included the year of study as a linear term in the
model, which turned out to be insignificant with a P
value of 0.07.
Blood donors and hospital setting (non-donor
population) by region
A total of 33 blood donor studies, of which 16 were
published [34-49] and 17 unpublished (Additional file 1:
Appendix; i-y). A total of 13 hospital-setting studies
were identified, of which 5 were published [50-54] and 8
unpublished (Additional file 1: Appendix; z-gg),
separated into region-specific outcomes. The weighted
mean prevalence (WMP) of HBsAg increases from
region A to C, from 2.53 to 4.25, respectively. The same
trend is seen in the weighted mean prevalence calcula-
tions in the hospital settings. For both study groups,
there were fewer studies in region C than in the other 2
regions (Table 2).
Pregnant women and military conscripts (age range, 17-
41 years)
The results for pregnant women [55-57] and military
recruits [58-61] are presented in Table 3. Military ser-
vice is compulsory in Turkey for men between the ages
of 17 and 39 years. The age range in the studies of preg-
nant women varied widely, from 17 to 41 years, which is
equivalent in range to that of the military recruits,
which is why we put these 2 study populations in the
same table. From the results of the WMP, we observed
a gender difference, which is 3.60% for military recruits
and 1.70% for pregnant women.
Health care workers and students
As there have been vaccination policies for health care
workers in Turkey since 1999, we separated the results
Figure 2 Flow diagram (Selection Strategy) of included studies.
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Page 4 of 12Table 1 Age- and Region-Specific HBsAg Prevalence in Turkey, 1999-2009
Age group Region
a
(yr) A B C
Ref N n %HBsAg 95% CI Ref N n %HBsAg 95% CI Ref N n %HBsAg 95% CI
0-14 a 420 14 3.33 1.83, 5.52 [12] 460 7 1.52 0.61, 3.11 [13] 402 13 3.23 1.73, 5.47
b 249 11 4.41 2.22, 7.76 [14] 875 26 2.97 1.95, 4.32 c 158 9 5.70 2.64, 10.54
d 230 6 2.60 0.96, 5.59 [15] 1131 80 7.07 5.64, 8.73 [16] 853 84 9.84 7.93, 12.04
e 1952 67 3.43 2.66, 4.34 f 1278 22 1.72 1.08. 2.59 [17] 700 29 4.14 2.79, 5.90
[18] 176 3 1.70 0.35, 4.90 [19] 420 13 3.10 1.66, 5.23 [20] 74 6 8.10 3.03, 16.81
[21] 6788 84 1.24 0.99, 1.53 g 100 2 2.00 0.24, 7.03 [22] 802 22 2.71 2.45, 2.97
[23] 423 8 1.89 0.82, 3.69 [24] 454 4 0.88 0.24, 2.24
Total 10238 193 1.88 1.63, 2.16 4718 154 3.26 2.77, 3.81 2989 163 5.45 4.66, 6.32
Total overall
b 17945 510 3.23 2.96, 3.53
15-24 [25] 129 6 4.65 1.72, 9.85 [12] 1058 43 4.06 2.96, 5.44 [13] 183 7 3.82 1.55, 7.72
[18] 440 46 10.45 7.75, 13.70 [26] 238 12 5.04 2.63, 8.64 [27] 213 46 21.60 16.27, 27-73
[21] 2822 178 6.31 5.44, 7.27 f 2431 114 4.69 3.88, 5.60 [20] 187 29 15.50 10.63, 21.50
[28] 7237 98 1.35 1.10, 1.65 [29] 350 11 3.14 1.58, 5.55 h 96 3 3.21 0.65, 8.86
[30] 155 20 13.00 8.06, 19.22
[24] 193 7 3.62 1.47, 7.32
[31] 340 22 6.47 4.09, 9.63
Total 10628 328 3.08 2.76, 3.43 4765 229 4.81 4.21, 5.45 679 85 12.51 10.12, 15.24
Total overall
b 15636 617 5.77 5.26, 6.32
25-34 [18] 226 18 7.97 4.79, 12.29 [12] 833 53 6.36 4.80, 8.24 [13] 219 19 8.67 5.30, 13.21
[21] 3674 235 6.40 5.62, 7.24 f 2431 114 4.69 3.88, 5.60 [27] 324 60 18.50 14.43, 23.18
[24] 193 7 3.62 1.47, 7.33 h 435 26 5.98 3.94, 8.63
[31] 238 12 5.04 2.63, 8.64
Total 3900 253 6.49 5.73, 7.30 3695 186 5.03 4.35, 5.78 978 105 10.73 8.86, 12.85
Total overall
b 7950 506 7.08 6.47-7.73
35-44 [18] 142 7 4.93 2.00, 9.89 [32] 85 10 11.76 5.79, 20.57 [13] 17 2 11.77 1.46, 36.44
[21] 4323 249 5.76 5.08, 6.49 [12] 741 71 9.58 7.55, 11.93 [27] 271 41 15.13 11.08, 19.96
f 3208 170 5.30 4.55, 6.13 h 555 38 6.84 4.90, 9.28
[24] 193 7 3.63 1.47, 7.33
[31] 173 7 4.05 1.64, 8.16
Total 4465 256 5.73 5.07, 6.45 4400 265 6.02 5.33, 6.76 843 81 9.60 7.70, 11.80
Total overall
b 8980 557 6.93 6.32, 7.60
45-54 [18] 85 7 8.23 3.37, 16.23 [32] 55 5 9.09 3.02, 19.95 [13] 17 2 11.76 1.46, 36.44
[21] 2170 100 4.60 3.76, 5.58 f 3208 170 5.30 4.55, 6.13 [27] 244 29 11.88 8.10, 16.62
[12] 288 27 9.37 6.27, 13.35 h 469 34 7.24 5.07, 9.98
[24] 346 12 3.47 1.80, 5.98
[31] 143 5 3.50 1.14, 7.97
Total 2255 107 4.75 3.90, 5.70 4040 219 5.42 4.74, 6.16 730 65 8.90 6.94, 11.20
Total overall‡ 6468 357 6.13 5.48, 6.85
55-64 [18] 32 0 0 0 f 4031 129 3.20 2.68, 3.79 [13] 17 2 11.76 1.46, 36.44
[21] 631 32 5.07 3.49, 7.08 [12] 56 1 1.78 0.05, 9.55 [27] 125 15 12.00 6.87, 19.01
[24] 346 12 3.47 1.80, 5.98 h 463 30 6.48 4.41, 9.12
[31] 118 11 9.32 4.75, 16.06
Total 663 32 4.83 3.32, 6.74 4551 153 3.36 2.85, 3.93 605 47 7.77 5.76, 10.19
Total overall
b 5238 191 5.03 4.29, 5.89
65+ [33] 165 15 9.09 5.17, 14.55 f 204 5 2.45 0.80, 5.63 [13] 17 2 11.76 1.46, 36.44
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Page 5 of 12into 2 sections. We compared the prevalence rates of
studies between 1990 and 1999, and 2000 and 2009 for
both health care workers (HCW) [62-83] and health
care students (HCS) [84-87]. Table 4 shows the decrease
in prevalence within the 10-year periods before and
after vaccination for HCW and HCS; the WMP
decreased from 3.34 to 2.29, and from 3.31 to 2.08,
respectively.
High-risk groups
To show the prevalence among those at high risk for
hepatitis B, we present the results for the following
groups: high-risk occupations; prison inmates; and
female sex workers. The high-risk occupation group
consisted of studies among hairdressers, butchers, gar-
b a g em e n ,a n dc o f f e eh o u s ew o r k e r s .T h e r ew e r e2s t u -
dies [88,89] that were eligible and used to calculate the
WMP, which was 7.63. There were 3 prison inmate stu-
dies, which were all unpublished (uu-ww) and yielded a
WMP of 6.73. Two studies, of which 1 was published
[90] and the other unpublished (Additional file 1:
A p p e n d i x ;x x ) ,w e r ea n a l y z e df o rt h ef e m a l es e xw o r k e r
(FSW) group, which yielded a WMP of 7.00.
Discussion
Age- and region-specific prevalence estimates
The age- and region-specific analysis relied primarily on
community-based studies from various regions. The
results yielded a marked difference in the overall region-
specific estimated prevalence, which ranged from 3.52 to
6.76. The age-specific prevalence also varied greatly
between the lowest prevalence in the age group of 0-14
years (2.84) and the highest prevalence, age group 25-34
years (6.36). The overall country-specific prevalence was
4.57, retrieved from the meta-analysis, across all regions
and age groups.
Region-specific, HBsAg-prevalence estimates for different
sample populations
Population sample groups such as blood donors have
been used as a convenient means to estimate the coun-
try-specific prevalence of HBV [4]. Since blood dona-
tion in Turkey is voluntary and the predonation
e l i g i b i l i t ya s s e s s m e n ti sq u i t es t r i c t ,ah e a l t h yd o n o r
effect prevails in this sample population, and likely
leads to an underestimation of the true HBV preva-
lence. Blood donors in this case cannot be representa-
tive of an entire population. Our results showed a
difference in the region-specific estimates, where the
weighted mean prevalence (WMP) ranges from 2.53 to
4.25. When compared with the age- and region-specific
outcomes, the results in this sample population are in
the low range, whereas the results in the hospital-set-
ting studies are in the high range. Thus, results based
on blood donors and from hospital settings should be
interpreted with caution.
Table 1 Age- and Region-Specific HBsAg Prevalence in Turkey, 1999-2009 (Continued)
[18] 89 2 2.24 0.27, 7.88 [24] 714 29 4.06 2.74, 5.78 [27] 127 10 7.87 3.84, 14.00
[21] 1115 35 3.14 2.20, 4.34 [31] 83 3 3.61 0.75, 10.20 h 1140 28 2.45 1.64, 3.53
Total 1369 52 3.80 2.84, 4.95 1001 37 3.70 2.61, 5.06 1284 40 3.11 2.23, 4.21
Total overall
b 2431 98 3.52 2.95-4.19
Overall Prevalence
c 4.57 3.58, 5.76
Abbreviations: N number of subjects, n number of cases, Ref reference
a Region A: Marmara and Aegean, B: Black Sea, Central Anatolia and Mediterranean, C: Eastern and south-eastern
b Total number of persons, cases and the pooled prevalence for each age-group
c The overall prevalence over all age-groups and the three regions
Table 2 Weighted mean region-specific HBsAg prevalence in blood donors and hospital settings
Study group %HBsAg prevalence (range)
Category no.studies N n Region* Weighted mean all data Weighted mean published data P value References
Blood donors 13 658662 16788 A 2.53 (1.10, 8.70) 2.33 (1.70, 2.75) 0.51 [34-40] (i-n)
16 223949 6389 B 2.68 (1.70, 4.22) 3.44 (2.60, 4.20) 0.14 [41-46] (o-x)
4 149918 6675 C 4.25 (1.70, 4.90) 4.45 (2.92, 4.90) 0.50 [47-49] (y)
Hospital† 5 37497 2977 A 3.40 (1.30, 13.80) 1.30 (0.90, 1.63) 0.40 [50] (z-cc)
6 100343 7781 B 7.15 (2.90, 13.60) 5.73 (2.90, 13.60) 1.00 [51,52] (dd-gg)
2 28392 6037 C - 10.88 (9.60, 21.30) - [53,54]
Abbreviations: N number of subjects, n number of cases
P value calculated by the two-sided Mann-Whitney test (difference in prevalence of all data and only published data)
* Region A: Marmara and Aegean, B: Black Sea, Central Anatolia and Mediterranean, C: Eastern and South-eastern
† Studies based in hospital settings on non-liver-related conditions
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dies is the military conscripts. Military service preva-
lence studies provide good estimates for the general
population of men between the ages of 17 and 41, while
pregnant women studies represent the comparable
female population of the same age range. Both these
sample groups are more representative than blood
donors and those from hospital settings. Although
screening for HBV in pregnant women is not yet routine
in Turkey, nonetheless pregnant women are likely to be
tested during their pregnancies, either for research or
for health purposes. Our WMP results comparing these
2 groups suggest that HBV is more prevalent among
males.
Strengths and limitations
The main strength of this systematic review is that it
includes all available Turkish studies, including both
published and unpublished abstracts (grey literature), to
overcome publication bias, and in particular language
bias. Due to the paucity of studies from Turkey on
hepatitis B in English, this review provides a wealth of
information that would not be accessible to scientists
and policy makers from other countries in the world.
We used an innovative approach to fit generalized linear
mixed models in estimating the prevalence from various
studies. Including the year of the study as a linear term
in the model showed no significant trend in prevalence
over time. Since prevalence is assumed to be not con-
stant, this could be a limitation of the model. Another
limitation may be the depend e n c eo nt h eq u a l i t yo ft h e
original reports. The strength of the study may also be a
weakness in that conventional wisdom points towards
an inverse correlation between quantity and quality.
Despite this limitation, we believe that the study
provides useful data on the epidemiology of hepatitis B
in Turkey for health planning strategies, both in Turkey
as well as in the Turkish migrant population. We sug-
gest that researchers who are preparing observational
research, such as sero-survey studies, implement the
STROBE guidelines [91] to ensure a clear presentation
of what was planned, done, and found in such a study.
Comparing the eras of pre-vaccination and post-
vaccination
Since the implementation of universal vaccination in
1998 of all children and risk groups, a decline in preva-
lence has been observed [4]. Although the current study
does not address this issue directly, the availability of
age-specific prevalence rates in the postvaccination era
enables us to make meaningful comparisons in children
from studies in the prevaccination era. In this context,
Kanra et al. [92] studied the prevalence in all regions of
Turkey among children before the vaccination policy
was implemented. Their finding of an overall country
prevalence of 5.90 among 0-15-year-olds compares
favourably to the current overall country prevalence rate
o f2 . 8 4r e p o r t e di nt h i ss t u d yf o rt h es a m ea g eg r o u p .
The impact of vaccination was also assessed in health
care workers and health care students. The WMP esti-
mates in the postvaccination studies show a decline,
which could be explained by the impact of the vaccina-
tion campaign or, as a secondary explanation, that HBV
has the tendency to decrease over the years. A study
from the United States shows patterns in the success of
vaccination application to health care workers [93].
Implications for health policy
Nearly every country with a large or diverse geographic
area is expected to have regional differences in HBV
Table 3 Weighted mean HBsAg prevalence in the military and in pregnant women
Study group %HBsAg prevalence (range)
Category no.studies N n Weighted mean all data Weighted mean published data P value Reference
Pregnant Women 4 6215 137 1.70 (1.31, 9.30) 1.60 (1.31, 3.50) 0.50 [55-57] (hh)
Military 5 90914 3539 3.60 (2.16, 9.80) 3.83 (2.16, 9.80) 0.80 [58-61] (ii)
P value calculated by the two-sided Mann-Whitney test (difference in prevalence of all data and only published data)
Table 4 Weighted mean HBsAg prevalence rates of health care workers and students before and after vaccination
Risk-group %HBsAg prevalence (range)
Category year no.studies N n Weighted mean all data Weighted mean published data P value Reference
HCW 1989-1999 15 4147 191 3.34 (1.60, 8.60) 3.86 (1.90, 8.00) 0.97 [62-74] (jj-kk)
HCW 2000-2009 15 5146 137 2.29 (1.40, 5.90) 2.35 (1.40, 5.90) 0.60 [75-83] (ll-qq)
HCS 1989-1999 4 1022 39 3.31 (2.40, 8.60) 3.42 (2.60, 8.60) 0.50 [84-86] (rr)
HCS 2000-2009 3 438 8 2.08 (1.00-2.40) 2.00 (0.20, 3.70) 1.00 [87] (ss-tt)
Abbreviations: N number of subjects, n number of cases, HCW health care worker, HCS health care student
P value calculated by the two-sided Mann-Whitney test (difference in prevalence of all data and only published data).
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can be very important. The large regional differences in
prevalence in Turkey are mainly due to differences in
socioeconomic status, lifestyles, infrastructure, and
access to health services. In the eastern and south-east-
ern regions (treated as 1 region) of Turkey, all reasons
mentioned above apply in a negative way, though the
latest years have witnessed much improvement in the
socioeconomic, and hygienic and sanitary conditions in
this region and in Turkey in general. This region also
lags behind in coverage of HBV vaccination. Although
only 18% of the total population live in this area, the
estimated number of CHB cases is almost equal to that
of the other regions, which have higher population
numbers (see Figure 1). A substantial migration has
taken place from the southeast and east to the west of
the country, mainly for economic reasons. The scarcity
of reports from southeast and east Turkey, despite the
magnitude of the CHB problem, may be an indirect
reflection of the health infrastructure of this region. The
region-specific data in this study could stimulate a
broad-based prevention and control campaign whereby
hepatitis B vaccines and/or treatment and monitoring
could be targeted to high-priority regions. Turkey has a
large proportion of young people (age 14-30 years,
which is more than 66% of the total population). It is a
dynamic society with a growing number of educated
people; further, the proportion of the population living
in cities has increased dramatically in recent decades
and now accounts for approximately 70% of the national
total. With an average prevalence of 3.50 in young peo-
ple age 0-24 years, hepatitis B remains a significant pub-
lic health problem in Turkey.
Another important facet of the data in this study is
linked to disease awareness, although this is certainly
not specific to Turkey, since CHB patients in general
are mostly asymptomatic. With an overall HBV preva-
lence of 4.57, the estimated number of HBV carriers in
Turkey is 3.3 million. Even a very conservative assess-
ment means that 10% of the carriers would need treat-
ment, yielding 330,000 chronic HBV cases eligible for
treatment in Turkey alone. We recently estimated that
treatment of CHB patients with active disease with a
low-resistance profile drug could reduce mortality
related to liver disease in this group by 80% [94]. It
needs to be stressed that in Turkey, viral hepatitis treat-
ment is fully reimbursed through the national insurance
system. According to net sold medication counts per
Figure 3 Age- and region-specific HBsAg prevalence, 1999-2009.
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patients receive active treatment [95], indicating a mas-
sive shortcoming in ensuring prolonged life and even
life-saving treatments. Chronic HBV infection is a life-
long illness. It can cause serious, life-threatening compli-
cations, such as cirrhosis, liver cancer, or liver failure.
Most liver transplants in Turkey are attributed to liver
disease from chronic HBV. A viral hepatitis national
plan should be designed that will lower hepatitis preva-
lence, increase research, and accelerate access to care
for the chronically infected. Testing for immunization
coverage should be instituted at the state and regional
level. Potential next steps would be to improve epide-
miologic surveillance systems, develop a hepatitis regis-
try, and implement serosurveys in order to produce
reliable data to guide prevention and control measures
and to monitor the impact of preventive strategies.
The importance of our study is certainly not confined
to the borders of Turkey. Recent evidence suggests that
the overall decline in HBV prevalence in the last decade
in industrialized countries of Europe appears to have
reached a plateau. The most likely reason why the pro-
gressive decline in HBV prevalence has come to a halt is
migration from endemic areas [96,97]. There are cur-
rently more than 3 million immigrants, descendants of
immigrants, and naturalized citizens and political refu-
gees from Turkey in Western Europe, representing the
largest immigrant group in the European Union. The
public health implications of the current study thus go
far beyond the border of Turkey.
Conclusions
Despite the availability of a safe and effective vaccine for
more than 20 years and because of its asymptomatic
nature, CHB remains a serious health problem. As this
study shows, the estimates of age- and region-specific
prevalence reflect the burden of existing CHB cases in
Turkey. Knowing the diversity in prevalence of CHB in
Turkey, public health organizations should turn their
attention, means, and actions increasingly to the areas
and groups that are lagging behind.
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